MedTrace Logo

Prognostic Value of Aβ Imaging in NPH Prior to Shunt Placement

NCT01834625 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 2

Last updated 2022-02-01

No results posted yet for this study

Summary

In this pilot study the investigators shall prospectively in a blinded fashion evaluate with Aβ PET in patients committed to shunt surgery and then investigate the relationship of these biomarkers with outcome on gait, cognition and urinary control improvement in the short term (3 months) and long term (1 year). The imaging agent will be provided by AVID.

Furthermore the study will standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden.

Conditions

  • Normal Pressure Hydrocephalus Patients

Interventions

DIAGNOSTIC_TEST

PET scan

Sponsors & Collaborators

Principal Investigators

  • Neill R Graff-Radford, MD · Mayo Clinic

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2017-03-31
Completion
2017-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01834625 on ClinicalTrials.gov